Latest Trovagene Inc. Stories
Industry leader with strong track record for commercializing disruptive life science and diagnostic technologies, and leveraging innovative applications of next-generation sequencing SAN
Advancing Its Precision Cancer Monitoring Platform Using Liquid Biopsy to Improve the Standard of Cancer Care SAN DIEGO, March 12, 2015 /PRNewswire/ -- Trovagene, Inc.
SAN DIEGO, Feb. 26, 2015 /PRNewswire/ -- Trovagene, Inc.
SAN DIEGO, Feb. 11, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced the closing of its previously announced underwritten public offering.
SAN DIEGO, Feb. 10, 2015 /PRNewswire/ -- Trovagene, Inc.
Large-scale study shows potential for non-invasive test to be made available to millions of women worldwide who are unscreened for the detection of cervical cancer SAN DIEGO, Feb.
SAN DIEGO, Feb. 6, 2015 /PRNewswire/ -- Trovagene, Inc.
MOUNTAIN VIEW, Calif., Jan.
Prospective clinical studies to evaluate Trovagene's Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA SAN DIEGO,
Trovagene's proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis SAN DIEGO,